Anavex Life Sciences Corp. (AVXL) Stock Price & Analysis
Anavex Life Sciences Corp. (AVXL) fell 3.05% to USD 2.54 as of June 10, 2026 at 04:25 UTC, according to Nexqual real-time market data.
AVXL last closed at USD 2.62; the session ranged USD 2.48–2.73 on volume of 857,670 shares. Market capitalization is $235.39M, with a 52-week range of USD 2.48–13.99 (NMS). Source: Nexqual, June 10, 2026 at 04:25 UTC.
Key Statistics (as of June 10, 2026 at 04:25 UTC)
| Price | USD 2.54 |
|---|---|
| Change | ▼ 3.05% (down) |
| Previous Close | USD 2.62 |
| Open | USD 2.65 |
| Day Range | USD 2.48 – 2.73 |
| 52-Week Range | USD 2.48 – 13.99 |
| Volume | 857,670 shares |
| Market Cap | $235.39M |
| Exchange | NMS |
Technical Analysis (AVXL)
Nexqual's technical model rates AVXL "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.74 (neutral) |
| vs SMA50 | Below (USD 3.08) |
| MACD | -0.15 (negative) |
Analyst Ratings (AVXL)
Wall Street analysts rate AVXL "Strong Buy" based on 1 analysts, with a mean price target of USD 20 (range USD 20–20), per Nexqual as of June 10, 2026 at 04:25 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 20 |
| High Target | USD 20 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (AVXL)
| Next Earnings Date | 2026-06-15 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.06 vs est -0.11 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.15 ▲ beat |
| 2025-06-30 | USD -0.16 vs est -0.15 ▼ miss |
| 2025-03-31 | USD -0.13 vs est -0.15 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:25 UTC.
Financials & Fundamentals (AVXL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -33.63% |
| Current Ratio | 20.87 |
| Total Cash | $131.75M |
| Total Debt | $0 |
| Free Cash Flow | $-21.83M |
Source: Nexqual, June 10, 2026 at 04:25 UTC.
Financial Health Score (AVXL)
Nexqual rates Anavex Life Sciences Corp.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:25 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $132M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$34M |
| Efficiency | Critical — ROE -34%, ROA -21.6% |
Ownership (AVXL)
| Insider Ownership | +3.12% |
|---|---|
| Institutional Ownership | +43.74% |
| Shares Outstanding | 92.67M |
| Float | 89.78M |
| Short % of Float | +21.15% |
Source: Nexqual, June 10, 2026 at 04:25 UTC.
Leadership (AVXL)
Anavex Life Sciences Corp. is led by Terrie Kellmeyer, Interim Chief Executive Officer, per Nexqual as of June 10, 2026 at 04:25 UTC.
| Interim Chief Executive Officer | Terrie Kellmeyer |
|---|
Major Backers & Investors (AVXL)
Notable institutional backers of Anavex Life Sciences Corp. include Two Sigma Investments, LP, Fidelity, Susquehanna International Group, LLP, according to Nexqual as of June 10, 2026 at 04:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Two Sigma Investments, LP | 3.5% |
| Fidelity | 1.44% |
| Susquehanna International Group, LLP | 1.07% |
| Summit Financial, LLC | 1.01% |
| Bank of America Corporation | 0.93% |
| Goldman Sachs | 0.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.92% |
| Vanguard Group | 9.55% |
| State Street | 7.99% |
| Geode Capital | 2.36% |
Source: Nexqual, June 10, 2026 at 04:25 UTC.
From Anavex Life Sciences Corp.'s Latest SEC 10-K Filing (filed 2025-11-25)
Key Strengths & Strategy (as disclosed to the SEC)
- With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX ® 2-73 (blarcamesine), our approach is to restore cellular balance (i.e. homeostasis).
- Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer side effects, are more convenient or are less expensive than any products that we may develop.   17     We believe our approach to the treatment of Alzheimer's disease and other CNS diseases differs from our competitors.
- Our platform may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1.
Partnerships
- The trial will utilize standard clinical outcome measures for schizophrenia including the Positive and Negative Symptoms Scale (PANSS), and novel fluid and electrophysiological biomarkers will also be assessed, leveraging several advances in electroencephalography/event-related potential (EEG/ERP) biomarkers in schizophrenia developed in collaboration with the industry-led ERP Biomarker Qualification Consortium.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANVS | Annovis Bio, Inc. | USD 1.77 | ▼ 6.35% |
| FLNA | Filana Therapeutics, Inc. | USD 1.42 | ▲ 7.58% |
| AXSM | Axsome Therapeutics, Inc. | USD 245.64 | ▲ 5.73% |
| AUPH | Aurinia Pharmaceuticals Inc | USD 15.78 | ▼ 0.38% |
| VERU | Veru Inc. | USD 3.1 | ▼ 8.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:25 UTC. This page is informational and not investment advice.